Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.68 |
| ▸ | DRD3 | P35462 | 14/20 | 0.68 |
| ▸ | DRD4 | P21917 | 8/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.62 |
| ▸ | HTR2A | P28223 | 3/20 | 0.62 |
| ▸ | HTR1A | P08908 | 3/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.62 |
| ▸ | DRD1 | P21728 | 2/20 | 0.62 |
| ▸ | HTR2C | P28335 | 2/20 | 0.62 |
| ▸ | HTR2B | P41595 | 2/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824386 | 0.97 | DRD2 (0.69) | DRD2DRD3DRD4ADRA1AHTR2A | |
| Maleic Acid SCHEMBL7831420 | 0.92 | DRD2 (0.63) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL14508968 | 0.86 | DRD2 (0.66) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809587 | 0.86 | DRD2 (0.64) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809585 | 0.84 | DRD3 (0.66) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809593 | 0.84 | ADRA1A (0.60) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809592 | 0.84 | DRD3 (0.66) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL7824678 | 0.83 | ADRA1A (0.69) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809607 | 0.82 | ADRA1A (0.63) | DRD2DRD3DRD4ADRA1AHTR2A | |
| SCHEMBL13809602 | 0.81 | DRD2 (0.60) | DRD2DRD3DRD4ADRA1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142351-A1 | Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | DRD2 2/4885DRD3 1/4885DRD4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.